Abstract

The invention relates to the use of acylated 4-amidinoor 4-guanidinobenzylamine in accordance with the general formula I

where P4 is a monosubstituted or polysubstituted or benzylsulfonyl unsubstituted group, Р3 is monosubstituted or polysubstituted or unsubstituted, natural or unnatural α -amino acid or α -imino acid in configuration, P2 is a monosubstituted polysubstituted or unsubstituted, natural or unnatural α -amino acid or α -imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted 4-amidino-4-quanidinobenzylamine unsubstituted or group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for administration anticoaqulants/systemic as antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.